Rosetta Genomics Ltd.NASDAQ
Apr. 9, 2015, 12:41 PM
- Rosetta Genomics (ROSG +0.7%) acquires CynoGen (d/b/a PersonalizeDx) from Prelude, a portfolio company of venture capital firm Fjord Ventures, for $2M in cash and 500K shares of ROSG stock.
- Lake Forest, CA-based PersonalizeDx provides cancer-related molecular diagnostics services to clinicians, pathologists and other reference laboratories in the U.S.
- The transaction will enable Rosetta to obtain the rights to Prelude's novel assay for ductal carcinoma in situ, the earliest form of breast cancer characterized by the presence of abnormal cells inside a milk duct in the breast.